Analysts & Consensus

Analysts & Consensus

A number of international financial analysts cover DSM. See the most recent consensus figures provided by Vara Research >
Q1 2018 Results

Q1 2018 Results

Strong underlying performance continues with well above market growth combined with exceptional industry supply disruptions & temporary higher prices for some vitamins results in significantly higher outlook for full year 2018 >
Company Presentation 2018

Company Presentation 2018

A concise introduction to, and overview of, DSM in 2018 >
Final dividend 2017

Final dividend 2017

Dividend for the financial year 2017 is €1.85 per ordinary share, an increase of €0.10 from the €1.75 paid for 2016 >

Q1 2018 Results

On Tuesday 8 May 2018 DSM published its Q1 2018 Results.

Commenting on the results, Feike Sijbesma, DSM's CEO and Chairman of the Managing Board said “We are very pleased that the strong underlying performance of our business continues, with growth well above market. In addition, we are currently benefitting from substantially higher prices in some vitamins due to exceptional supply disruptions in the industry, which are expected to be temporary and heavily weighted towards the first half of the year. These two combined resulted in a significantly higher outlook for the full year 2018, which we announced with our preliminary Q1 2018 results on 12 April 2018.”